A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor. eligible participants will initiate oral therapy with YY-20394 at a starting dose of 80mg taken once per day. treatment with YY-20394 can continue in compliant participants as long as the study is still ongoing and the participants appear to benefiting from treatment with acceptable safety.
Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Diffuse Large B Cell Lymphoma
DRUG: YY-20394
Adverse events evaluated by NCI CTCAE V5.0, incidence of adverse events and associated dose of YY-20394, Throughout the study for approximately 2 years|Overall response rate, the percentage of participants achieving a complete response or partial response, Throughout the study for approximately 2 years|disease control rate, the percentage of participants achieving a complete response or partial response or stable disease, Throughout the study for approximately 2 years
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor. eligible participants will initiate oral therapy with YY-20394 at a starting dose of 80mg taken once per day. treatment with YY-20394 can continue in compliant participants as long as the study is still ongoing and the participants appear to benefiting from treatment with acceptable safety.